Welcome to our dedicated page for Marimed news (Ticker: MRMD), a resource for investors and traders seeking the latest updates and insights on Marimed stock.
MariMed Inc. (MRMD) generates frequent news as a multi-state cannabis operator and cannabis consumer packaged goods company focused on branded products, facility operations, and regulatory developments. Its releases cover both corporate performance and brand-level activity across cultivation, production, and retail channels.
On this page, readers can follow MariMed’s earnings announcements, where the company discusses revenue trends, gross margins, net income or loss, and non-GAAP measures such as Adjusted EBITDA. These updates often include commentary on wholesale and retail performance, as well as progress on what management calls its "Expand the Brand" strategy to grow top-selling cannabis brands.
MariMed’s news flow also highlights product and brand developments. Examples include new limited-edition Betty’s Eddies™ fruit chews, extensions to the Nature’s Heritage™ product line, and initiatives for Vibations™ and InHouse™. The company reports on licensing and managed services agreements that bring its brands into additional states, as well as strategic decisions such as exiting specific markets after operational reviews.
In addition, MariMed issues releases on community and veteran-focused initiatives tied to its Thrive dispensaries and brands, along with commentary on major policy changes affecting cannabis, such as the rescheduling of cannabis at the federal level. Investors and observers can use this news feed to monitor how MariMed communicates its strategy, brand expansion, financial performance, and responses to regulatory and market changes over time.
MariMed (CSE: MRMD; OTCQX: MRMD) will report its fourth quarter and full year 2025 financial results on March 11, 2026 after market close. Management will host a conference call on March 12, 2026 at 8:00 a.m. EDT with a live webcast and playback available via MariMed investor relations.
MariMed (MRMD) launches a limited-edition Valentine’s seasonal: Berry In Love Betty, a strawberry-chocolate swirled fruit chew infused with full-spectrum cannabis, CBG, and horny goat weed. Available Feb 2026 at Thrive Dispensary locations and other retailers in Massachusetts, Maryland, Illinois, and Delaware.
The chew is vegan, gluten-free, dairy-free, and is positioned as a libido-enhancing seasonal offering from the Betty’s Eddies brand.
MariMed (CSE: MRMD / OTCQX: MRMD) launched a hemp-derived THC version of its Vibations hydrating drink mix in Rhode Island on Jan 22, 2026. Each stick contains 5mg THC; initial flavors are Lemon Lime (Sugar Free), Half & Half, Strawberry Lemonade, and Tropical Punch. Distribution is through licensed Rhode Island liquor stores (more than 150 approved locations) via Craft Collective Homegrown, with sales and local marketing by Modern Infusions. The company plans to evaluate early performance and may expand distribution into additional markets in H1 2026, while noting potential regulatory risk from pending federal legislation.
MariMed (CSE: MRMD / OTCQX: MRMD) issued a CEO statement on Dec. 18, 2025 responding to federal rescheduling of cannabis to Schedule III. The company called the move the "single greatest cannabis reform" and said it formally recognizes medical uses and lower abuse potential.
The statement says rescheduling will accelerate accredited medical research, expand consumer adoption as an alternative to opioids, and end the IRS Section 280E tax penalty for state-legal cannabis businesses—allowing compliant operators to be taxed like other consumer packaged goods sectors and, the company says, materially improve profitability and free cash flow.
MariMed (CSE: MRMD; OTCQX: MRMD) debuted an original song, Thrive: Anna, written by U.S. Army veteran and dispensary customer Ryan Taylor to celebrate his recovery and the welcoming environment at Thrive Dispensary in Anna, Illinois.
The company will play the song in-store across all 13 Thrive Dispensary locations in Massachusetts, Ohio, Delaware, Maryland, and Illinois, include a prerecorded introduction by a veteran team member, and make a donation to nonprofit FreedomSingsUSA in Taylor’s honor. Thrive: Anna is available for streaming on YouTube.
MariMed (CSE: MRMD / OTCQX: MRMD) launched a limited-edition winter flavor for its Betty’s Eddies cannabis fruit chews called Bundle Up Betty’s on Nov 18, 2025.
The seasonal chew combines real cranberry, orange, and warming spices and is infused with a relaxing blend of THC and CBD. Bundle Up Betty’s is available at select cannabis retailers and MariMed Thrive dispensaries in Massachusetts, Maryland, Illinois, and Delaware, and can be located via www.bettyseddies.com.
MariMed (CSE: MRMD, OTCQX: MRMD) reported third quarter results for the period ended September 30, 2025, with revenue of $40.8M and GAAP gross margin ~40%. The company reported a GAAP net loss of $2.9M for the quarter and a non-GAAP adjusted EBITDA of $5.1M.
Operationally, MariMed expanded branded distribution and management agreements: licensing Betty’s Eddies to Maine (July 14), a Managed Services Agreement and Pennsylvania licensing with TILT (July 31) with distribution anticipated in 2026, a New York licensing agreement (Oct 23) targeting 2026 distribution, and hemp‑derived THC manufacturing and distribution deals (Nov 3) with expected Rhode Island availability by early 2026. Management will host a conference call on Nov 6, 2025 at 8:00 AM ET.
MariMed (CSE: MRMD / OTCQX: MRMD) announced manufacturing and distribution agreements to launch hemp-derived THC versions of its beverage and edibles brands, including Vibations and Betty’s Eddies.
A hemp-derived THC Vibations drink mix is expected to be available in Rhode Island by early Q1 2026. The agreements establish an end-to-end hemp THC supply chain and create a new business unit, MMA Hemp Inc.
Partners named include DeHydr8 (manufacturing tech), Countermeasures (national sales/marketing), and Craft Collective Homegrown (Rhode Island distribution). According to BDSA, the hemp beverage market was $3.3B in 2024 and is projected to nearly double by 2029. Vibations and Betty’s Eddies are cited as top-selling brands in MariMed core markets.
MariMed (CSE: MRMD / OTCQX: MRMD) announced it has completed a strategic review and is exiting the Missouri market, effective immediately.
Since 2024 the company managed another licensed operator's Missouri facility under a Managed Services and Licensing Agreement while awaiting a license transfer; MariMed will no longer manage the facility or pursue the license transfer. The company continues to own or manage revenue-generating operations in six states, including 13 dispensaries and six cultivation and processing facilities across Delaware, Illinois, Maryland, Massachusetts, Ohio, and Pennsylvania. MariMed said the exit is expected to improve gross margin and adjusted EBITDA and let management redeploy resources to higher-return core markets. Management said it may consider future licensing with a vertical operator in Missouri if financially sensible.
MariMed (CSE: MRMD / OTCQX: MRMD) announced a licensing agreement with Farm 2 Hand to introduce MariMed’s top-selling edibles across New York State.
Farm 2 Hand will manufacture and distribute Betty’s Eddies™, Bubby’s Baked™, and InHouse™ gummies from a new kitchen that MariMed will design and equip at Farm 2 Hand’s Bronx facility. Terms were not disclosed. MariMed expects products to reach New York’s 500+ dispensaries in 2026, pending the kitchen build-out and regulatory approval. The company cited New York’s $6 billion total addressable market as a strategic expansion opportunity to drive wholesale revenue and brand awareness.